Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Core Insights - Revolution Medicines, Inc. is set to report its financial results for Q4 and the full year 2024 on February 26, 2025, after market close [1] - A webcast will be hosted by the senior management team at 4:30 p.m. ET to discuss the financial results and corporate progress [1] Company Overview - Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company's R&D pipeline includes RAS(ON) inhibitors such as daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), which are currently in clinical development [3] - Additional pipeline opportunities include RAS(ON) mutant-selective inhibitors like RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C) [3]